Hypoxia-driven immunosuppression: A new reason to use thermal therapy in the treatment of cancer?
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Hypoxia within the tumour microenvironment is correlated with poor treatment outcome after radiation and chemotherapy, and with decreased overall survival in cancer patients. Several molecular mechanisms by which hypoxia supports tumour growth and interferes with effective radiation and chemotherapies are now well established. However, several new lines of investigation are pointing to yet another ominous outcome of hypoxia in the tumour microenvironment: suppression of anti-tumour immune effector cells and enhancement of tumour escape from immune surveillance. This review summarises this important information, and highlights mechanistic data by which hypoxia incapacitates several different types of immune effector cells, enhances the activity of immunosuppressive cells and provides new avenues which help 'blind' immune cells to detect the presence of tumour cells. Finally, we discuss data which indicates that mild thermal therapy, through its physiologically regulated ability to alter vascular perfusion and oxygen tensions within the tumour microenvironment, as well as its ability to enhance the function of some of the same immune effector activities that are inhibited by hypoxia, could be used to rapidly and safely release the tight grip of hypoxia in the tumour microenvironment thereby reducing barriers to more effective immune-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 5×
“New data from our lab shows that systemic or whole body hyperthermia treatment can significantly decrease tumour interstitial fluid pressure (IFP) to a comparable level achieved in Taxol treatment, a common chemotherapy drug that has been shown to decrease tumour IFP (Arindam Sen et al., unpublished MSS).”
BackgroundInfluentialCellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“T cells have been shown to increase expression of certain genes which are regulated by HIF (VEGF, glycolytic enzymes) after exposure to hypoxia [71–73].”
BackgroundHypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158 · cited 1×
“A two- or three-fold higher radiation dose is needed to kill hypoxic tumour cells compared to well-oxygenated cells [14, 44, 45].”
BackgroundHypoxia-inducible factor 1: master regulator of O2 homeostasis
Semenza, G. L. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80016-6 · Cited by 1,092
Skin blood flow in adult human thermoregulation: How it works, when it does not, and why
Charkoudian, N. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.5.603 · Cited by 1,041
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022
Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix
Höckel, M., Knoop, C., Schlenger, K., Vorndran, B., Bauβnann, E., Mitze, M., Knapstein, P. G., & Vaupel, P. (1993) · Radiotherapy and Oncology · doi:10.1016/0167-8140(93)90025-4 · Cited by 809 · cited 1×
“In a cervical cancer study published in 1993, it was found that the extent of hypoxia positively correlated with a more negative prognosis [17, 18].”
BackgroundInterdependence of hypoxic and innate immune responses
Nizet, V., & Johnson, R. S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2607 · Cited by 708 · cited 2×
“New data suggests that hypoxia appears to entrap TAMs by decreasing their mobility [91, 93, 94].”
BackgroundHypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α
Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R. D., Engh, J., Iwama, T., Kunisada, T., Kassam, A. B., et al. (2009) · Oncogene · doi:10.1038/onc.2009.252 · Cited by 656 · cited 1×
“A higher thermal dose (443 C) leads to decrease of tumour oxygenation possibly because of blood vessel damage [40, 108, 114, 116–118].”
BackgroundEnergy Metabolism of Human Neutrophils during Phagocytosis
Borregaard, N., & Herlin, T. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110647 · Cited by 503 · cited 1×
“Phagocytes may need to adapt to the hypoxic environment to generate energy and function efficiently [86].”
BackgroundCaldwell, C. C., Kojima, H., Lukashev, D., Armstrong, J., Farber, M., Apasov, S. G., & Sitkovsky, M. V. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6140 · Cited by 420
Cosse, J.-P., & Michiels, C. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785914798 · Cited by 348 · cited 1×
“HIF-1 expression in tumours has been reported to induce epithelial to mesenchymal transition (EMT) in colon cancer, increase expression of angiogenic factors such as VEGF, and increased genetic instability [35, 36].”
BackgroundGrantab, R., Sivananthan, S., & Tannock, I. F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3077 · Cited by 254
Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer
Yamamoto, Y., Ibusuki, M., Okumura, Y., Kawasoe, T., Kai, K., Iyama, K., & Iwase, H. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9742-1 · Cited by 151 · cited 1×
“reported that certain clones within the tumour can react favourably to hypoxic conditions, leading to tumour progression [25, 26].”
BackgroundHarada, H., Itasaka, S., Zhu, Y., Zeng, L., Xie, X., Morinibu, A., Shinomiya, K., & Hiraoka, M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604939 · Cited by 82 · cited 1×
“Using inhibitors to HIF-1 or proteins involved in its regulation could provide a way to increase the sensitivity of tumours to radiation therapy [48, 49].”
BackgroundIoannou, M., Papamichali, R., Kouvaras, E., Mylonis, I., Vageli, D., Kerenidou, T., Barbanis, S., Daponte, A., Simos, G., Gourgoulianis, K., et al. (2009) · Lung · doi:10.1007/s00408-009-9169-z · Cited by 57 · cited 1×
“For example, in a recent study it was shown that lung cancer cells express high levels of HIF-1 and are resistant to radiation-induced cell death [46, 47].”
Background
Cited by
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066
“resistance and immune-suppression, which help tumor cells to escape from immune surveillance.(117,118) Some of the”
BackgroundRegulation of glycolysis by the hypoxia-inducible factor (HIF): Implications for cellular physiology
Kierans, S. J., & Taylor, C. T. (2021) · The Journal of Physiology · doi:10.1113/jp280572 · Cited by 1,015
“While physiological hypoxia can promote immune cell homeostasis under hypoxic conditions by altering immune cell metabolic status, pathological hypoxia, as evident in the core of tumours can regulate immune cell effector function which in turn plays a role in tumour development (Lee et al. 2010).”
BackgroundKeck, M. K., Zuo, Z., Khattri, A., Stricker, T. P., Brown, C. D., Imanguli, M., Rieke, D., Endhardt, K., Fang, P., Brägelmann, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2481 · Cited by 370
Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., van Moer, K., Medves, S., Zimmer, J., Oudin, A., Niclou, S. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304790110 · Cited by 344
Nitric Oxide in Macrophage Immunometabolism: Hiding in Plain Sight
Palmieri, E. M., McGinity, C., Wink, D. A., & McVicar, D. W. (2020) · Metabolites · doi:10.3390/metabo10110429 · Cited by 237
“Of consequence, the increased available pO2 associated with elevated NO levels can affect the immune response [234].”
Background
Metadata
- Authors
- Lee, C.-T., Mace, T., & Repasky, E. A.
- Venue
- International Journal of Hyperthermia
- Publisher
- Informa UK Limited
- Published
- 2010-01-01
- Volume
- 26
- Issue
- 3
- Pages
- 232-246
- ISSN
- 0265-6736 (ISSN-L)
- 1464-5157
- OpenAlex
- W1990489521
- Cited by
- 103
- References
- 17
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.